CJC-1295 Without DAC (Mod GRF 1-29): The Definitive Research Guide & Purchasing Brief

Executive Summary & Product Overview

CJC-1295 Without DAC, technically classified as Modified GRF 1-29 (Tetrasubstituted GRF 1-29), represents one of the most widely studied synthetic peptide analogs of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Engineered specifically to target somatotroph cells within the anterior pituitary gland, this 29-amino-acid peptide plays a pivotal role in endocrinological research focused on pulsatile human growth hormone (hGH) dynamics.

For laboratory researchers across Australia seeking high-grade, analytical-quality reagents, sourcing CJC-1295 Without DAC requires strict adherence to purity metrics, chemical stability standards, and verifiable manufacturing processes. Unlike extended-release peptide formulations, CJC-1295 No DAC provides a controlled, short-duration physiological window. This makes it an ideal reference tool for investigating acute metabolic pathways, cellular repair mechanisms, and endocrine feedback loops.

Chemical Structure & Mechanism of Action

To understand the operational mechanics of CJC-1295 Without DAC, one must compare it to native GHRH (which consists of 44 amino acids). Native GHRH undergoes extremely rapid cleavage by the endogenous enzyme dipeptidyl peptidase IV (DPP-IV), resulting in a biological half-life of less than 5 minutes.

Modified GRF 1-29 addresses this instability through four targeted amino acid substitutions at critical positions:

• Ala2 to D-Ala2: Provides immediate resistance against enzymatic degradation by DPP-IV.

• Gln8 to Gln8 (or Ala8): Optimizes receptor binding kinetics and structural integrity.

• Asp15 to Ala15: Enhances chemical stability and reduces acid hydrolysis pathways.

• Asn27 to Lys27: Reduces deamidation, extending overall shelf-life in solution.

Because CJC-1295 Without DAC omits the Drug Affinity Complex (DAC)—a maleimido-derivative reactive group that binds covalently to serum albumin—it does not circulate in systemic blood plasma for days. Instead, it exhibits a clean, transient half-life of approximately 30 minutes.

This transient half-life allows researchers to trigger sharp, targeted pulses of growth hormone release without elevating baseline GH levels for extended periods. This preservation of natural pulsatility avoids continuous pituitary receptor down-regulation, making it a preferred subject for acute release protocols.

Primary Research Benefits & Applications

Laboratory research into CJC-1295 Without DAC centers primarily around metabolic, anabolic, and restorative biological pathways:

• Pulsatile Growth Hormone Stimulation: By selectively activating pituitary GHRH receptors, CJC-1295 No DAC stimulates discrete bursts of GH release. This enables precise study of natural circadian GH kinetics.

• Hepatic IGF-1 Induction: Downstream activation of the GH axis elevates liver production of Insulin-Like Growth Factor 1 (IGF-1), a primary driver of nitrogen retention, cell proliferation, and protein accretion.

• Adipose Tissue Metabolism (Lipolysis): Elevated acute GH levels stimulate lipolytic cascades, mobilizing stored triglycerides into free fatty acids for oxidative energy production.

• Connective Tissue & Musculoskeletal Repair: Research models suggest that co-regulated GH and IGF-1 secretion accelerates collagen synthesis, aiding the study of tendon, ligament, and skeletal muscle remodeling.

• Synergistic Secretagogue Pairing: In experimental frameworks, combining CJC-1295 Without DAC with a Growth Hormone Releasing Peptide (GHRP, such as Ipamorelin or GHRP-2) creates a synergistic amplification effect, yielding a significantly higher GH peak than either agent administered in isolation.

Reconstitution, Handling & Storage Guidelines

Maintaining the structural stability of CJC-1295 Without DAC requires specific laboratory protocols:

Ordering CJC-1295 Without DAC Online in Australia

When sourcing research peptides online in Australia, verification of product quality is paramount. Analytical integrity relies on two main quality control standards:

1. High-Performance Liquid Chromatography (HPLC): Confirms that chemical purity meets or exceeds 99.0%.

2. Mass Spectrometry (MS): Verifies exact molecular weight matches the theoretical sequence of Mod GRF 1-29 ($MW \approx 3367.9\text{ g/mol}$).

Reputable Australian vendors supply batch-specific Certificates of Analysis (CoA) to guarantee that research reagents are free from heavy metal contamination, leftover synthesis reagents, or un-modified sequence fragments. All products are supplied strictly for in vitro laboratory experimentation and analytical evaluation.